Cinrebafusp alfa not checked
Pieris Pharmaceuticals, Inc. · PRS-343 · HER2/41BB Bispecific
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- HER2-positive Gastric Cancer
- Main trialPhase 2
- “A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.”In the company’s words, NCT05190445 on ClinicalTrials.gov
- Other names
- PRS-343 · HER2/41BB Bispecific
Other drugs for HER2-positive Gastric Cancer
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 1 Feb 2023 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | |
| Phase 1Completed | 11 Aug 2022 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | |
| Phase 1Completed | 1 Dec 2023 | PRS-343 in HER2-Positive Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026